Astellas Pharma Inc.
Astellas Pharma Inc. (ALPMY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
alpmy · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Astellas Pharma Inc. (ALPMY) measures how much investors pay for each dollar of the company's trailing earnings. ALPMY's current PE ratio of 13.21x is calculated by dividing its stock price of $13.49 by its TTM earnings per share of $162.37. −78.1% discount vs 5Y avg 60.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2013 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 14 fiscal years · Front-end computedMinQ1 · 25%26.7x
MedianQ3 · 75%171.7x
Max
At 13.21x, ALPMY's current P/E is lower than in 0% of its annual fiscal year readings over the past 14 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Astellas Pharma Inc.You ALPMY | $24.2B | 13.21x | -44.5% | $162.37 |
 bioMérieux S.A. BMXXY | $9.9B | 33.13x | +39.2% | $0.32 |
 CSPC Pharmaceutical Group Limited CHJTF | $12.0B | 22.34x | -6.2% | $0.33 |
 Grifols, S.A. GIKLY | $14.2B | 18.68x | -21.5% | $0.28 |
 Genmab A/S GNMSF | $15.3B | 19.58x | -17.8% | $16.04 |
 Orion Oyj ORINY | $22.9B | 36.71x | +54.2% | $0.85 |
 Otsuka Holdings Co., Ltd. OTSKF | $34.6B | 12.41x | -47.9% | $685.66 |
Industry Average 6 peers with valid PE | — | 23.81x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 14.92x | $172.58 | -70.9% | |
2025-03-31 FY2025 | 51.29x | $28.24 | -70.1% | |
2024-03-31 FY2024 | 171.73x | $9.51 | +394.2% | |
2023-03-31 FY2023 | 34.75x | $54.24 | +23.0% | |
2022-03-31 FY2022 | 28.25x | $67.08 | +7.4% | |
2021-03-31 FY2021 | 26.32x | $64.93 | +67.3% | |
2020-03-31 FY2020 | 15.73x | $104.15 | +6.4% | |
2019-03-31 FY2019 | 14.79x | $115.05 | -26.1% | |
2018-03-31 FY2018 | 20.02x | $81.11 | +41.4% | |
2017-03-31 FY2017 | 14.16x | $103.69 | -15.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Astellas Pharma Inc. (ALPMY) measures how much investors pay for each dollar of the company's trailing earnings. ALPMY's current PE ratio of 13.21x is calculated by dividing its stock price of $13.49 by its TTM earnings per share of $162.37.
Frequently asked questions
ALPMY pe ratio · 6 questionsALPMY's current PE ratio is 13.21x as of 2026-06-09, based on a stock price of $13.49 and TTM EPS of $162.37. Data sourced from Financial Modeling Prep via ALPMY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09